INDIANAPOLIS — Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment. Lilly had expected the Food and Drug Administration to decide on donanemab’s approval by the end of the month. But the drugmaker said Friday that … Read more
The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the memory-robbing disease. The biotech company will focus on rolling out … Read more
Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of … Read more
Health Canada has green lit a drug previously approved for schizophrenia and depression to treat symptoms of agitation in Alzheimer’s patients. Rexulti (brexpiprazole) oral tablets manufactured by Otsuka Pharmaceutical Canada Inc. and Lundbeck Canada Inc. were issued a Notice of Compliance by the regulator, according to a company release Wednesday. This approval was given after … Read more
In May 2021, Heather Sosa, a Vancouver resident, received distressing news from her husband’s medical professionals — they diagnosed him with a mental illness and admitted him to a hospital out of fear for his safety. But as time unfolded, it became apparent that the initial diagnosis was incorrect. Contrary to the earlier assessment, Heather’s … Read more
Alzheimer’s sufferers may soon be able to receive a diagnosis for the disease years before symptoms appear, thanks to a groundbreaking new blood test. Scientists believe a new blood test capable of measuring levels of a known marker protein that precedes the development of the debilitating neurodegenerative disease. A study by Alzheimer’s researchers has found … Read more
Alzheimer’s disease is the most common cause of dementia in the UK. It’s progressive condition, meaning symptoms develop gradually over many years, eventually becoming more severe. It affects multiple brain functions, but one of the first symptoms, according to NHS doctor, Dr James O’Donovan, is memory lapses. Having amassed more than 25,000 followers on TikTok, … Read more
WASHINGTON — Scientists have found a way to help Alzheimer’s drugs seep inside the brain faster — by temporarily breaching its protective shield. The novel experiment was a first attempt in just three patients. But in spots in the brain where the new technology took aim, it enhanced removal of Alzheimer’s trademark brain-clogging plaque, researchers … Read more
NEW YORK — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna’s stock on … Read more
